Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 0591-4385

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 0591-4385). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula Image (Image 1)

Chemical structure diagram showing the molecular formula of fosaprepitant, the active ingredient in Fosaprepitant injection, powder, lyophilized, for solution. The diagram illustrates the atoms and bonds comprising fosaprepitant with clear structural detail.*

FDA Label Image

Carton (Image 2)

Packaging label for Fosaprepitant for Injection 150 mg/vial, sterile lyophilized powder for intravenous use supplied by Actavis Pharma, Inc. The label includes preparation instructions, dosage warnings, and storage conditions. It also details the vial contents, noting 150 mg fosaprepitant equivalent to 245.3 mg fosaprepitant dimeglumine, and cautions against use with certain solutions. The label displays barcodes, serialization coding area, and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.